SEATTLE--(BUSINESS WIRE)--According to Coherent Market Insights, the global tissue plasminogen activator market is estimated to be valued at US$ 2,455.4 million in 2020 and is expected to exhibit a ...

A new analysis supports the use of intravenous (IV) tenecteplase over IV alteplase (tissue plasminogen activator) for treatment of acute ischemic stroke. The analysis found that patients with ischemic ...

To test the hypothesis that the tissue plasminogen activator (tPA) may counteract the inhibitory effect of plasminogen activator inhibitors (PAI) and attenuate lung injury in a rat model of ventilator ...

Clinical characteristics and outcome of cancer patients with tuberculosis. This is an ASCO Meeting Abstract from the 2015 ASCO Annual Meeting I. This abstract does not include a full text component.

PHILADELPHIA -- Current anticoagulant or antiplatelet use is not necessarily a contraindication for administering tissue plasminogen activator (tPA) to a stroke patient in the emergency department, a ...

LOS ANGELES — The cost of tissue plasminogen activator (tPA; alteplase, Genentech) has more than doubled over the past decade, but Medicare/Medicaid reimbursement has not kept pace, new research shows ...

To the Editor: Hemmelgarn et al. (Jan. 27 issue) 1 evaluated prophylactic recombinant tissue plasminogen activator (rt-PA) for preventing dialysis catheter malfunction. I have a few caveats regarding ...

Team finds closed plasminogen conformation transiently exposes binding site. Scientists report the X-ray crystal structure of full-length human plasminogen, and describe binding of blood clots to ...